Log In
Print this Print this

elotuzumab (BMS-901608, HuLuc63) (formerly PDL 063)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionHumanized mAb targeting cell-surface glycoprotein CS1
Molecular Target Cell-surface glycoprotein CS1
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat relapsed or refractory multiple myeloma (MM)
Regulatory Designation

U.S. - Breakthrough Therapy (Treat relapsed or refractory multiple myeloma (MM));
Switzerland - Orphan Drug (Treat multiple myeloma (MM))


Bristol-Myers Squibb Co.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today